PT  - JOURNAL ARTICLE
AU  - Brown, Taylor
AU  - Kanel, Prabesh
AU  - Carli, Giulia
AU  - Barr, Jaimie
AU  - Bohnen, Nicolaas I.
AU  - Albin, Roger L.
TI  - Cognitive and Cholinergic Systems Trajectories in Parkinson Disease
AID  - 10.1101/2024.07.17.24310588
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.17.24310588
4099  - http://medrxiv.org/content/early/2024/07/17/2024.07.17.24310588.short
4100  - http://medrxiv.org/content/early/2024/07/17/2024.07.17.24310588.full
AB  - Objective Cognitive decline in Parkinson disease (PD) is a disabling and highly variable non-motor feature. While cholinergic systems degeneration is linked to cognitive impairments in PD, most prior research reported cross-sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ligand [18F]-fluoroethoxybenzovesamicol ([18F]-FEOBV) binding predicts longitudinal cognitive changes in mild to moderate, non-demented PD subjects.Methods Seventy-five non-demented, mild-moderate PD subjects received baseline standardized cognitive evaluations and [18F]-FEOBV PET imaging with repeat cognitive evaluations 2 years later. Participants were classified into four cognitive classes based on stability or change in cognition: Persistent normal (no MCI at baseline and follow-up), Persistent MCI, MCI conversion, and MCI reversion. Whole-brain voxel comparisons with normal controls, and voxel-based and cluster volume-of-interest correlation analyses with longitudinal cognitive changes were performed.Results Whole-brain voxel comparisons of each class with a matched control group revealed unique bi-directional differences in baseline regional [18F]-FEOBV binding. Increased regional [18F]-FEOBV binding in predominantly anterior cortical and sub-cortical regions was found in the persistent normal and MCI reversion groups. Whole-brain voxel correlation analysis between baseline [18F]-FEOBV binding and two-year longitudinal percent changes in cognition identified a specific regional pattern of reduced posterior cortical, limbic and paralimbic [18F]-FEOBV binding predictive of global cognitive declines and across five cognitive domains at two-year follow-ups.Interpretation Cholinergic system changes correlate with varying cognitive trajectories in mild-moderate PD. Upregulation of cholinergic neurotransmission may be an important compensatory process in mild-moderate PD.Competing Interest StatementRoger Albin serves on the Data Safety and Monitoring Boards for the CELIA, SIGNAL-AD, TOPAS-MSA, and Zilgenersen trials. The other authors report no competing interests.Funding StatementThis study was funded by the National Institutes of Health, the Department of Veterans Affairs, and the Parkinsons Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs of the University of Michigan and the VA Ann Arbor Health System gave ethical approvals for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes